Table 1.
Study | Year | Country | Study design | Diagnosis | Study perspective | Inputs included in cost analysis* | Cost outcomes (in 2018 USD) | CHEERS checklist (out of 24) |
Multiple childhood cancers | ||||||||
Bhakta et al 17 | 2013 | Brazil and Malawi | CA, CEA, CUA | ALL and BL | N/A | N/A | Cost-effectiveness thresholds (using 3% discounting): ALL in Brazil: Upper limit of cost effective: $560 106 per case Upper limit of very cost effective: $186 701 per case BL in Malawi: Upper limit of cost effective: $30 273 per case Upper limit of very cost effective: $10 091 per case |
21 |
Fuentes-Alabi et al 18 | 2018 | El Salvador | CA, CEA, CUA | All childhood cancers | Hospital | Comprehensive | Annual cost to maintain paediatric cancer treatment programme: $5 440 465 Cost per newly diagnosed patient per year: $30 035 Cost per DALY averted using 3% discounting: $1699 |
23 |
Jasso-Gutierrez et al 41 | 2012 | Mexico | CA | ALL and HL | Not specified | Low | Cost of cancer drugs (remission induction stage and consolidation): ALL: Standard-risk ALL: $4982 for 20 kg child and $6663 for 30 kg child High-risk and very high-risk ALL: $5575 for 20 kg child and $7456 for 30 kg child HL: Stages IA and IIA: $222 for 20 kg child and $277 for 30 kg child. Stages IB and IIB: $2735 for 20 kg child and $3659 for 30 kg child. Stages III and IV: $2883 for 20 kg child and $3857 for 30 kg child |
16 |
Neal et al 49 | 2018 | Rwanda | CA | WT and HL | Hospital | Comprehensive | WT: cost per treated patient per year: $1913 ($1362–$1913) HL: cost per treated patient per year: $1638 ($1042–$1638) |
22.5 |
Renner et al 16 | 2018 | Ghana | CA, CEA, CUA | All childhood cancers | Hospital | Comprehensive | Annual cost to operate a paediatric cancer unit: $1 791 797. Cost per newly diagnosed patient per year: $10 540 Cost per life saved: $30 115 Cost per DALY averted using 3% discounting: $1114 |
22 |
Leukaemias | ||||||||
Jaime-Perez et al 40 | 2017 | Mexico | CA | ALL | Public health system, hospital and patient | Medium | Cost per treated patient: $20 954 to $24 788. | 20 |
Gao et al 31 | 2013 | China | CA | ALL | Patient | Low | Cost per treated patient: ALL-BFM 2002: median $14 124 ($8003–$50 002) ALL China-98: median $27 209 ($17 156–$79 334) |
16 |
Garcia et al 32 | 2015 | Colombia | CA, CEA | AML | Heath system | Low | Cost per treated patient: Chemotherapy only: $14 731 Unrelated transplant: $65 486 Related transplant: $85 114 ICER for related transplant compared with chemotherapy: $2744 ICER for unrelated transplant compared with chemotherapy: $3868 |
23 |
Ghatak et al 33 | 2016 | India | CA | ALL | Patient | Comprehensive | During first month of therapy (induction phase): Cost of medical expenditure per patient: $574 (IQR $433–$851). Total cost of nonmedical expenditure per patient: $227 (IQR $156–$322). |
19 |
Gu et al 34 | 2008 | China | CA | ALL | Patient | Low | Cost per treated patient was $26 800 for low-risk, $35 734 for medium-risk and $44 667 for high-risk patients, respectively. | 13.5 |
Hayati et al 35 | 2018 | Iran | CUA | ALL | Not specified | Medium | Cost per treated patient: UK-ALL protocol: $9323 BFM-ALL protocol: $16 914 Cost per QALY gained: UK-ALL protocol: $2104 BFM-ALL protocol: $4475 |
18 |
Islam et al 38 | 2015 | Bangladesh | CA | ALL | Patient | Comprehensive | Cost per treated patient: $5684 ($4182–$9814) | 21 |
Jayaraman et al 42 | 2017 | India | CA | ALL | Not specified | Low | Cost of each vial of Peg-asparaginase was $2309 Each vial of 3750 units/mL was shared among 3–4 children. |
14.5 |
Liu et al 45 | 2009 | China | CA | ALL | Hospital | Medium | Costs per treated patient: $17 295±10 914 ($8782–78 218) | 18.5 |
Luo et al 46 | 2008 | China | CA | ALL | Patient | Medium | China-98 protocol: Cost per treated patient (median and range): $18 791 ($13 064–$38 487) Modified ALLIC BFM200 protocol: Cost per treated patient (median and range): $14 953 ($10 370–$29 142) Economic protocol: Cost per treated patient (median and range): $6391 ($4683–$10 250) |
19 |
Luo et al 47 | 2009 | China | CA | APL | Not specified | Low | Cost per treated patient: In-house protocol: median $24 704 ($16 305–$34 092) Modified PETHEMA protocol: median $5806 ($3335–$10 623) |
11.5 |
Rocha-Garcia et al 51 | 2003 | Mexico | CA | ALL | Patient | Medium | Cost per treated child: $719 | 18 |
Wilms tumour | ||||||||
Israels et al 39 | 2018 | Malawi, Cameroon and Ghana | CA | WT | Patient | Low | Cost per treated patient: $105–$1151. | 15.5 |
Kanyamuhunga et al 44 | 2015 | Rwanda | CA | WT | Hospital and patient | Medium | Cost per treated patient: $1796 for early stage and $2372 for advanced disease stage | 19.5 |
Paintsil et al 50 | 2015 | Ethiopia, Ghana, Cameroon, Malawi and Uganda | CA | WT | Patient | Medium | Cost per treated patient: Komfo Anokye Teaching Hospital (Ghana): $1110 Korle Bu Teaching Hospital (Ghana): $1110 Uganda Cancer Institute (Uganda): $211 Queen Elizabeth Central Hospital (Malawi): $122 Mbingo, Mutengene and Banso Baptist Hospitals (Cameroon): $416 Tikur Anbessa Specialised Hospital (Ethiopia): $388 |
17 |
Burkitt lymphoma | ||||||||
Denburg et al 30 | 2019 | Uganda | CA, CEA, CUA | BL | Government | Comprehensive | Cost per treated child US$1401 Annual national cost of treatment: $864 854 Cost per DALY averted using 3% discounting $100 |
23.5 |
Hesseling et al 37 | 2003 | Malawi | CA | BL | Not specified | Low | Cost per treated patient: <$217 | 12.5 |
Meremikwu et al 48 | 2005 | Nigeria | CA | BL | Patient | Medium | Cost for a 7 years old child with BL (including 6-course treatment regimen): $141 | 16.5 |
Traoré et al 53 | 2011 | Burkina-Faso, Cameroon, Ivory Coast, Madagascar, Mali, and Senegal | CA | BL | Not specified | Low | Cost per treated child: $799 | 12.5 |
Hodgkin lymphoma | ||||||||
Stefan and Stones52 | 2009 | South Africa | CA | HL | Not specified | Low | HL stage II: cost per treated child $7360 | 18.5 |
Retinoblastoma | ||||||||
Ji et al 43 | 2012 | China | CA | Retinoblastoma | Patient | Comprehensive | Cost per treated patient: $9954±$3919 Medical costs: $7250±$3659 Non-medical costs: $2705±$1424 |
20 |
Waddell et al 54 | 2015 | Uganda | CA | Retinoblastoma | Not specified | Low | Cost per treated child: $1079. | 12.5 |
Yao et al 55 | 2018 | DRC and Ivory Coast | CA | Retinoblastoma | Not specified | Low | Cost per treated child: Lubumbashi (DRC): $1475 Kinshasa (DRC): $879 Bukavu (DRC): $637 Abidjan (Ivory Coast): $527 |
10.5 |
Other | ||||||||
Agarwal et al 29 | 2007 | India | CA | Osteosarcoma | Patient | Low | Cost of rotationplasty: $661 including cost of prosthesis Cost of indigenous non-expandable prosthesis: $1321 Cost of expandable prosthesis: $33 029 |
13.5 |
Hendricks et al 36 | 2011 | South Africa | CA | Extracranial germ cell tumours | Not specified | Low | Cost per treated patient by treatment regimen: Cisplatin (×3 cycles) $2470. Carboplatin (×4 cycles $529, (×5 cycles) $662, (×6 cycles) $794 | 16 |
*Comprehensive: ≥10 inputs, Medium: 5–9 inputs, Low: <5 inputs.
ALL, acute lymphoblastic leukaemia; AML, acute myeloid leukaemia; APL, acute promyelocytic leukaemia; BL, Burkitt lymphoma; CA, cost analysis; CEA, cost-effectiveness analysis; CUA, cost-utility analysis; DALY, disability-adjusted life year; DRC, Democratic Republic of Congo; HL, Hodgkin lymphoma; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year; WT, Wilms tumour.